Last reviewed · How we verify
Ivabradine and Metoprolol
This combination reduces heart rate through dual action: ivabradine selectively inhibits the If channel in the sinoatrial node, while metoprolol blocks beta-1 adrenergic receptors.
This combination reduces heart rate through dual action: ivabradine selectively inhibits the If channel in the sinoatrial node, while metoprolol blocks beta-1 adrenergic receptors. Used for Heart failure with reduced ejection fraction (HFrEF) with elevated resting heart rate, Stable angina pectoris, Chronic heart failure.
At a glance
| Generic name | Ivabradine and Metoprolol |
|---|---|
| Sponsor | Col. Suthee Panichkul |
| Drug class | Combination: If channel inhibitor and beta-1 adrenergic antagonist |
| Target | If channel (HCN4) and beta-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Ivabradine is a selective inhibitor of the funny current (If) in cardiac pacemaker cells, slowing heart rate without affecting contractility or blood pressure. Metoprolol is a beta-1 selective antagonist that reduces heart rate and cardiac workload through adrenergic blockade. Together, they provide complementary heart rate reduction for patients with heart failure or angina who require more aggressive rate control.
Approved indications
- Heart failure with reduced ejection fraction (HFrEF) with elevated resting heart rate
- Stable angina pectoris
- Chronic heart failure
Common side effects
- Bradycardia
- Fatigue
- Dizziness
- Hypotension
- Visual disturbances (ivabradine-related)
Key clinical trials
- Heart Rate Control Before Cardiac Computed Tomography in Adults for the Evaluation of Coronary Artery Disease (PHASE2, PHASE3)
- Role of Ivabradine on Heart Rate and Quality of Life in Patients With Mitral Stenosis in Sinus Rhythm (PHASE4)
- " Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD " (PHASE2, PHASE3)
- Heart Rate Controller in Computed Tomography Coronary Angiography (PHASE4)
- Effects of Heart Rate Reduction on Central Arterial Pressure in Healthy Individuals (PHASE4)
- Efficacy and Safety of Ivabradine to Reduce Heart Rate Prior to Coronary CT-angiography in Advanced Heart Failure: Comparison With β-Blocker (NA)
- Comparison of Efficacy of Ivabradine Versus Metoprolol (PHASE4)
- The Influence of Heart Rate Reduction Upon Central Arterial Pressure in Younger and Older Healthy Individuals (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |